Development & Manufacture of Oral and Topical Dosage Forms

发展

• 批准号: 7789041
• 负责人: ROLLAND R POUST
• 金额: $ 20万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7789041
• 关键词: Development; Manufacture; Oral; Topical; Dosage

The Developmental Therapeutic Program (DTP) of the Division of Cancer Treatment and Diagnosis (DCTD) is involved in discovery and development of new therapeutic agents for treatment of cancer. One of the essential parts of this mission involves the manufacture and supply of dosage forms to support human clinical trials under NCI sponsorship or through investigator-initiated INDs. Molecules for development enter the system under various mechanisms such as the ¿Drug Development Group (DDG)¿, ¿Rapid Access to Intervention Development (RAID)¿, or ¿Joint Development Committee (JDC)¿. The current contract provides the NCI with pharmaceutical development and production of oral and topical dosage forms for use in clinical trials, advanced Pharmacology, and IND-directed Toxicology testing.

癌症治疗和诊断部（DCTD）的发展治疗计划（DTP）参与发现和开发用于治疗癌症的新治疗剂。这项使命的重要组成部分之一是生产和供应剂型，以支持NCI赞助或通过制药商发起的IND进行的人体临床试验。用于开发的分子在各种机制下进入系统，如药物开发组（DDG）、快速干预开发（RAID）或联合开发委员会（JDC）。目前的合同为NCI提供药物开发和生产口服和局部剂型，用于临床试验，高级药理学和IND指导的毒理学测试。